Shares of TrovaGene Inc (NASDAQ:TROV) ended Tuesday session in red amid volatile trading. The shares closed down -0.15 points or -3.01% at $4.83 with 225,047.00 shares getting traded. Post opening the session at $4.90, the shares hit an intraday low of $4.75 and an intraday high of $5.00 and the price vacillated in this range throughout the day. The company has a market cap of $152.66 million and the numbers of outstanding shares have been calculated to be 30.15 million shares.
TrovaGene Inc (TROV) on Aug. 17, 2016 announced that it has signed an in-network provider agreement with the healthcare network Blue Cross Blue Shield of Illinois (BCBSIL) establishing health benefit access to the full line of Trovagene’s tests and services.
“The agreement with BCBSIL takes us a step further in the execution of our access and reimbursement strategy that includes establishing relationships with leading national and regional payors,” said Bill Welch, Chief Executive Officer of Trovagene. “We are looking forward to offering oncologists and their patient’s access to our Trovera™ urine and blood based liquid biopsy tests and enabling personalized cancer care.”
Trovagene now has contracts with payors covering approximately 168 million lives. Increasing patient access by contracting with payors is one of the critical strategic components that support the adoption of Trovagene’s clinical testing in late-stage solid tumor cancers.
Shares of Prima BioMed Ltd (ADR) (NASDAQ:PBMD) ended Tuesday session in green amid volatile trading. The shares closed up +0.020 points or 2.27% at $0.900 with 91,968.00 shares getting traded. Post opening the session at $0.95, the shares hit an intraday low of $0.89 and an intraday high of $0.97 and the price vacillated in this range throughout the day. The company has a market cap of $60.69 million and the numbers of outstanding shares have been calculated to be 68.97 million shares.
Prima BioMed Ltd (ADR) (PBMD) on Aug 24, 2016 announced the granting of patent number 2142210 entitled “Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease” by the European Patent Office.
The patent relates to Prima’s IMP731 antibody (originally developed by Immutep SAS). The granted claims provide protection for specific sequences of anti-LAG-3 antibodies and their use in depleting LAG-3+ T cells by complement dependent cytotoxicity (CDC) and antibody-dependent cell cytotoxicity (ADCC).
Rights for the development of the IMP731 antibody were granted in December 2010 to GSK, which has commenced first-in-human clinical trials of the proprietary antibody (GSK2831781) derived from IMP731.